Linda S. Steelman

16.3k total citations · 5 hit papers
112 papers, 11.2k citations indexed

About

Linda S. Steelman is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Linda S. Steelman has authored 112 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Molecular Biology, 53 papers in Oncology and 17 papers in Organic Chemistry. Recurrent topics in Linda S. Steelman's work include PI3K/AKT/mTOR signaling in cancer (39 papers), Melanoma and MAPK Pathways (24 papers) and Cancer-related Molecular Pathways (24 papers). Linda S. Steelman is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (39 papers), Melanoma and MAPK Pathways (24 papers) and Cancer-related Molecular Pathways (24 papers). Linda S. Steelman collaborates with scholars based in United States, Italy and Germany. Linda S. Steelman's co-authors include James A. McCubrey, Richard A. Franklin, Massimo Libra, Alberto M. Martelli, Stephen L. Abrams, Patrick M. Navolanic, Franca Stivala, J G Shelton, William L. Blalock and William H. Chappell and has published in prestigious journals such as Blood, Cancer Research and Oncogene.

In The Last Decade

Linda S. Steelman

112 papers receiving 11.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

2006 1.9k citations James A. McCubrey, Linda S. Steelman et al. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research profile →
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy

2003 999 citations Patrick M. Navolanic, Linda S. Steelman et al. profile →
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention

2003 577 citations Linda S. Steelman, Patrick M. Navolanic et al. profile →
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

2004 555 citations Linda S. Steelman, Richard A. Franklin et al. profile →
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

2006 550 citations James A. McCubrey, Linda S. Steelman et al. Advances in Enzyme Regulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Linda S. Steelman United States	49	7.5k	3.3k	1.9k	1.2k	1.2k	112	11.2k
Zhiwei Wang China	65	8.8k 1.2×	4.4k 1.3×	3.4k 1.8×	1.0k 0.9×	983 0.8×	250	13.6k
Andrew S. Kraft United States	55	6.9k 0.9×	3.4k 1.0×	1.1k 0.6×	1.9k 1.6×	807 0.7×	180	10.7k
Richard A. Franklin United States	41	5.8k 0.8×	2.4k 0.7×	1.3k 0.7×	853 0.7×	789 0.7×	146	9.5k
Alfonso Bellacosa United States	52	10.8k 1.4×	4.0k 1.2×	2.3k 1.2×	2.0k 1.7×	420 0.4×	118	14.4k
Patrick Auberger France	52	6.5k 0.9×	2.1k 0.6×	2.1k 1.1×	494 0.4×	1.1k 0.9×	193	10.5k
Nicholas Mitsiades United States	66	10.1k 1.3×	4.5k 1.4×	2.4k 1.3×	1.1k 0.9×	4.6k 4.0×	172	15.3k
Shi‐Yong Sun United States	56	7.2k 0.9×	2.7k 0.8×	1.5k 0.8×	767 0.6×	401 0.3×	203	9.5k
Brett P. Monia United States	77	13.9k 1.8×	3.3k 1.0×	3.4k 1.8×	821 0.7×	1.8k 1.5×	274	21.8k
Saverio Minucci Italy	60	14.2k 1.9×	3.0k 0.9×	1.7k 0.9×	444 0.4×	2.8k 2.4×	193	17.0k
Mayumi Ono Japan	61	7.4k 1.0×	4.0k 1.2×	2.2k 1.2×	823 0.7×	326 0.3×	214	12.1k

Countries citing papers authored by Linda S. Steelman

Since Specialization

Citations

This map shows the geographic impact of Linda S. Steelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda S. Steelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda S. Steelman more than expected).

Fields of papers citing papers by Linda S. Steelman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda S. Steelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda S. Steelman. The network helps show where Linda S. Steelman may publish in the future.

Co-authorship network of co-authors of Linda S. Steelman

This figure shows the co-authorship network connecting the top 25 collaborators of Linda S. Steelman. A scholar is included among the top collaborators of Linda S. Steelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda S. Steelman. Linda S. Steelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blumenthal, Deborah T., Ingo K. Mellinghoff, Martin J. van den Bent, et al.. (2023). 498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma. Annals of Oncology. 34. S391–S391. 2 indexed citations

Abrams, Stephen L., Shaw M. Akula, Linda S. Steelman, et al.. (2021). Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Advances in Biological Regulation. 83. 100840–100840. 6 indexed citations

Akula, Shaw M., Stephen L. Abrams, Linda S. Steelman, et al.. (2020). Cancer therapy and treatments during COVID-19 era. Advances in Biological Regulation. 77. 100739–100739. 33 indexed citations

Duda, Przemysław, Shaw M. Akula, Stephen L. Abrams, et al.. (2020). GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1867(10). 118770–118770. 15 indexed citations

Akula, Shaw M., Stephen L. Abrams, Linda S. Steelman, et al.. (2019). RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opinion on Therapeutic Targets. 23(11). 915–929. 71 indexed citations

Chappell, William H., Saverio Candido, Stephen L. Abrams, et al.. (2018). Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation. 69. 43–62. 19 indexed citations

Abrams, Stephen L., Kvin Lertpiriyapong, Li V. Yang, et al.. (2018). Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation. 69. 16–34. 27 indexed citations

McCubrey, James A., Dariusz Rakus, Agnieszka Gizak, et al.. (2016). Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1863(12). 2942–2976. 131 indexed citations

McCubrey, James A., Timothy L. Fitzgerald, Li V. Yang, et al.. (2016). Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. 8(8). 14221–14250. 88 indexed citations

10.

McCubrey, James A., Stephen L. Abrams, Timothy L. Fitzgerald, et al.. (2014). Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Advances in Biological Regulation. 57. 75–101. 102 indexed citations

11.

Ciuffreda, Ludovica, Ursula Cesta Incani, Linda S. Steelman, et al.. (2014). Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC. Current Pharmaceutical Design. 20(24). 3944–3957. 52 indexed citations

12.

McCubrey, James A., Nicole D. Armstrong, Stephen L. Abrams, et al.. (2013). Diverse roles of GSK-3: Tumor promoter–tumor suppressor, target in cancer therapy. Advances in Biological Regulation. 54. 176–196. 75 indexed citations

13.

Chappell, William H., Stephen L. Abrams, Giuseppe Montalto, et al.. (2012). Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity. Oncotarget. 3(10). 1236–1245. 12 indexed citations

14.

Steelman, Linda S., Patrick M. Navolanic, William H. Chappell, et al.. (2011). Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 10(17). 3003–3015. 70 indexed citations

15.

Abrams, Stephen L., Linda S. Steelman, John G. Shelton, et al.. (2010). Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle. 9(9). 1839–1846. 21 indexed citations

16.

McCubrey, James A., William H. Chappell, Stephen L. Abrams, et al.. (2010). Targeting the cancer initiating cell: The Achilles’ heel of cancer. Advances in Enzyme Regulation. 51(1). 152–162. 9 indexed citations

17.

McCubrey, James A., Linda S. Steelman, Steven L. Abrams, et al.. (2009). Emerging Raf inhibitors. Expert Opinion on Emerging Drugs. 14(4). 633–648. 26 indexed citations

18.

Libra, Massimo, Grazia Malaponte, Giovanni Ligresti, et al.. (2007). Activation of MAPK and AKT pathways by BRAF, NRAS and PIK3CA mutations in melanoma. Cancer Research. 67. 155–155. 1 indexed citations

19.

McCubrey, James A., John G. Shelton, Linda S. Steelman, et al.. (2004). Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene. 23(47). 7810–7820. 12 indexed citations

20.

Steelman, Linda S., Fred E. Bertrand, & James A. McCubrey. (2004). The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opinion on Therapeutic Targets. 8(6). 537–550. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact